P-tau 217 Specificity to Alzheimer's Disease

Diagnostic Performance

Elevated plasma p-tau217 is highly specific to Alzheimer's disease pathology and is not significantly elevated in other tauopathies or neurodegenerative diseases, with increased levels observed in AD and not in other conditions such as primary age-related tauopathy, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and frontotemporal lobar degeneration syndromes 1
Plasma p-tau217 demonstrates exceptional ability to differentiate AD from other neurodegenerative diseases, with levels increased 250-600% in AD dementia compared to non-AD neurodegenerative diseases 1

Certain factors such as cerebrovascular disease and cardiovascular disease may influence p-tau217 measurements and require careful interpretation 2
Age, creatinine levels, and depressive symptoms are biological confounders that may affect p-tau217 measurements 3

Elevated p-tau217 is essentially pathognomonic for Alzheimer's disease pathology when using high-performing assays, and if p-tau217 is elevated in a patient with dementia, this strongly indicates AD pathology rather than other neurodegenerative conditions 1
When p-tau217 is normal but cognitive impairment exists, clinicians should actively consider alternative diagnoses such as frontotemporal dementia or corticobasal degeneration 3

Not all p-tau assays perform equally, and clinicians must use validated high-performing platforms to ensure accurate results, with lower-performing assays potentially producing misleading results 1, 2, 3